Mark Mallon

Executive Senior Advisor, Ironwood Pharmaceuticals.

Companies

NeoGenomicsBoard member Apr 21, 2021 to Mar 3, 2022¹
NeoGenomicsChief executive officer Apr 21, 2021 to Mar 3, 2022¹
Ironwood PharmaceuticalsBoard member Apr 3, 2019 to Mar 2, 2021²
Ironwood PharmaceuticalsChief executive officer Apr 3, 2019 to Mar 2, 2021²
Ironwood PharmaceuticalsExecutive Senior Advisor Jan 11, 2019 to Jan 11, 2019³

Holdings

Stock this person has reported owning, from the forms officers and directors file with the SEC. See the biggest insider stakes.

Shares held

NeoGenomics NEO368,051 shares⁴$6.1M at $16.48Mar 1, 2022

As of each latest filing. The line shows shares held over time.

Recent filings

Mar 1, 2022Granted 142,457 shares of NeoGenomics⁴
Dec 30, 2021Granted 152,858 shares of NeoGenomics⁵
Dec 6, 2021Bought 17,000 shares at $30.63 of NeoGenomics⁶

Sources

The numbers on this page point here. Each one links to the record it came from.

1
SEC EDGARNeoGenomics, Board member
2
SEC EDGARIronwood Pharmaceuticals, Board member
3
SEC EDGARIronwood Pharmaceuticals, Executive Senior Advisor
4
SEC EDGARNeoGenomics shares after the filing of Mar 1, 2022
5
SEC EDGARForm 4 filed Dec 30, 2021
6
SEC EDGARForm 4 filed Dec 6, 2021